(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.On (b)(6) 2016 (12:57): troponin i=0.00 ng/ml, upper reference limit 0.5.Post-procedure: on (b)(6) 2016 (14:45): ecg=no myocardial infarction.On (b)(6) 2016 (22:02): ck=66 u/l, normal upper limit 234.On (b)(6) 2016 (22:02): ck-mb=2.3 ng/ml, normal upper limit 6.3.On (b)(6) 2016 (09:44): ck=54 u/l, normal upper limit 234.On (b)(6) 2016 (09:44): ck-mb=2.1 ng/ml, normal upper limit 6.(b)(4).There was no reported device malfunction and the product was not returned.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of intimal dissection is listed in the nc trek rx, global, instructions for use as a known patient effect.Based on the case information and related record review, a conclusive cause for the reported patient effect and the relationship to the product, if any, cannot be determined and there is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that on (b)(6) 2016, a 3.0x15mm nc trek dilatation catheter performed pre-dilatation on a mid-left anterior descending (lad) coronary artery, 70% stenosed lesion.Following, a dissection was noted, treated with the planned 3.0x18mm xience alpine stent.The dissection resolved without sequela.On (b)(6) 2016, the patient was discharged home.There was no additional information provided.
|